Home Clinical trials For patients Ovary BGOG-ov83/CATALINA-2

BGOG-ov83/CATALINA-2

A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women with Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

Open
Trial drug
TORL-1-23
Grade
High grade
Prior lines
1, 2, 3
Histology
Serous, Endometrioid
Platin
Platinum resistant
Secondary platinum refractory
Phase
II

Treatment

The treatment option in this study is TORL-1-23.
TORL-1-23 is given intravenously every 3 weeks.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.